<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607759</url>
  </required_header>
  <id_info>
    <org_study_id>UCAMCFE-00017</org_study_id>
    <nct_id>NCT04607759</nct_id>
  </id_info>
  <brief_title>Clinical Trial on the Articular Pain With a Cucumber Supplement in Patients Diagnosed With Arthrosis</brief_title>
  <acronym>CUCART</acronym>
  <official_title>Randomized Clinical Trial to Analyze the Efficacy of a Supplement Removed From Cucumber on the Articular Pain of Diagnosed Patients of Arthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Católica San Antonio de Murcia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, controlled, double-blind clinical trial of two parallel branches to analyze the&#xD;
      efficacy of a supplement extracted from the cucumber on the joint pain of patients diagnosed&#xD;
      with osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects that meet the selection criteria will make a total of two visits to the research&#xD;
      laboratory and will carry out the pre-established tests in the protocol. Subsequently, a&#xD;
      statistical analysis will be carried out with the variables measured in the study to obtain&#xD;
      results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Actual">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain from baseline at 8 weeks</measure>
    <time_frame>The pain will be measured by a scale twice, at the beginning and at the end of the study (after an 8 week consumption).</time_frame>
    <description>Visual analog scale from 0 to 10. The higher the value, the more pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in concomitant analgesic medication</measure>
    <time_frame>Twice, once at the beginning of the trial in basal conditions and once at the end after 8 weeks of consumption.</time_frame>
    <description>The change in the need for the use of analgesic medications will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life test: WOMAC test</measure>
    <time_frame>it will be measured twice, once at baseline or at the end of the study after 8 weeks of use</time_frame>
    <description>The quality of life of the subjects will be measured with the WOMAC test. It is a 24-item test that will measure the degree of pain: nothing, little, enough, a lot, and a lot, when performing activities in daily life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional test</measure>
    <time_frame>Twice, once at the beginning of the trial in basal conditions and once at the end after 8 weeks of consumption.</time_frame>
    <description>The balance and mobility of the subjects will be measured with the Timed Up and Go Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function</measure>
    <time_frame>Twice, once at the beginning of the trial in basal conditions and once at the end after 8 weeks of consumption.</time_frame>
    <description>Isokinetic dynamometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory state IL-b</measure>
    <time_frame>Twice, once at the beginning of the trial in basal conditions and once at the end after 8 weeks of consumption.</time_frame>
    <description>It is a blood test that measures cartilage degradation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cartilage metabolism</measure>
    <time_frame>Twice, once at the beginning of the trial in basal conditions and once at the end after 8 weeks of consumption.</time_frame>
    <description>It is a blood test that measures cartilage degradation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver safety variables</measure>
    <time_frame>Twice, once at the beginning of the trial in basal conditions and once at the end after 8 weeks of consumption.</time_frame>
    <description>It is a blood test that measures the presence of some enzymes, proteins and bilirubin in the blood, with the aim of determining if there is any alteration in the liver. Enzyme GPT, GOT, Gamma GT, LDH, alkaline phosphatase and bilirubin (UI/L)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Experimental group (cucumber)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption for 90 days of cucumber extract (20mg/day)&#xD;
Two capsules a day orally for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group Placebo (sucrose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two capsules a day orally for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>nutraceutical</intervention_name>
    <description>Subjects will consume two capsules for eight weeks</description>
    <arm_group_label>Experimental group (cucumber)</arm_group_label>
    <arm_group_label>control group Placebo (sucrose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 40 years.&#xD;
&#xD;
          -  Subjects diagnosed with osteoarthritis with functional grades I-III according to the&#xD;
             modified criteria of the American College of Rheumatology.&#xD;
&#xD;
          -  Subjects must have persistent knee pain associated with osteoarthritis with a baseline&#xD;
             score of at least 30 mm on the VAS pain assessment.&#xD;
&#xD;
          -  Subjects should not present narcotic drugs or steroidal anti-inflammatory drugs or&#xD;
             immunosuppressants in their treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious or terminal illnesses.&#xD;
&#xD;
          -  Subjects currently taking glucosamine, chondroitin sulfate, collagen or hyaluronic&#xD;
             infiltrations or any supplement indicated for joint health.&#xD;
&#xD;
          -  Subjects with chronic inflammatory diseases that affect the musculoskeletal system&#xD;
             (rheumatoid arthritis, gout, pseudo-gout, Paget's disease, chronic pain syndrome,&#xD;
             etc.).&#xD;
&#xD;
          -  Subjects with a body mass index above 32.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Inability to understand informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University of Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Católica San Antonio de Murcia</investigator_affiliation>
    <investigator_full_name>Francisco Javier López Román</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

